Coastlands Capital LP filed a Form 4 with the SEC on November 10, 2026, disclosing a purchase of 50,000 shares of common stock in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) on November 9, 2026.
Key Highlights
- Transaction: Coastlands Capital LP acquired 50,000 shares of Bolt Biotherapeutics common stock on November 9, 2026.
- Weighted average price: The shares were purchased at a weighted average price of $6.38 per share.
- Price range: Individual transactions occurred at prices ranging from $6.3618 to $6.4044 per share.
- Post-transaction ownership: Following the purchase, Coastlands Capital LP beneficially owns 462,416 shares indirectly.
- Reporting person relationship: Coastlands Capital LP is identified as a 10% owner of Bolt Biotherapeutics.
- Control person: Matthew Perry is identified as the control person of Coastlands, Coastlands Capital Partners LP, Coastlands Capital GP LLC, and Coastlands Capital LLC.
Coastlands Capital LP Discloses Open-Market Purchase in Bolt Biotherapeutics
According to the Form 4 filed on November 10, 2026, Coastlands Capital LP, a 10% owner of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), reported the purchase of 50,000 shares of the company's common stock. The transaction, coded "P" for an open-market purchase, took place on November 9, 2026. The filing states that the weighted average purchase price was $6.38 per share, with individual transactions executed at prices ranging from $6.3618 to $6.4044 per share.
The filing notes that Coastlands Capital LP and Coastlands Capital GP LLC serve as the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership described as the "Partnership." Coastlands Capital LLC is identified as the general partner of Coastlands. Matthew Perry is named as the control person of Coastlands, the Partnership, Coastlands Capital GP LLC, and Coastlands Capital GP LLC. The beneficial ownership of 462,416 shares reported following the transaction is held indirectly by Coastlands Capital LP.
The filing was signed by Mark Shamia, identified as Chief Operating Officer of the General Partner of Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, and Coastlands Capital LLC, as well as by Matthew D. Perry, all on November 10, 2026. The filing further states that each reporting person "disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein," and that the reporting persons are filing jointly but "not as members of a group," with each disclaiming group membership.
What Was Disclosed
Coastlands Capital LP reported an open-market purchase of 50,000 shares of Bolt Biotherapeutics common stock on November 9, 2026, at a weighted average price of $6.38 per share, bringing its indirectly held beneficial ownership to 462,416 shares.



Please wait processing your request...